Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Key facts

Study ID
NCT03444870
Run by
Hoffmann-La Roche
People needed
1053
Starts
2018-06-06
Expected to finish
2023-02-17
Last updated by the study team
2024-01-30

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.